Replimune Group, Inc. (REPL) earnings date
Feb 11, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q3 FY2027
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 40 days, typically, give or take 19 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q2 FY2027 | Wed, Oct 28, 2026 | before open | 28 | 8-K |
| Q1 FY2027 | Fri, Aug 14, 2026 | before open | 45 | 8-K |
| Q4 FY2026 | Mon, Jun 29, 2026 | before open | 90 | 8-K |
| Q3 FY2026 | Tue, Feb 3, 2026 | before open | 34 | 8-K |
| Q2 FY2026 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q1 FY2026 | Thu, Aug 7, 2025 | before open | 38 | 8-K |
| Q4 FY2025 | Thu, May 22, 2025 | before open | 52 | 8-K |
| Q3 FY2025 | Wed, Feb 12, 2025 | before open | 43 | 8-K |
What they guided beta
| Q1 FY2027 | "The primary endpoint, expected to readout in 2030, is overall survival, and key secondary" exhibit |
| Q1 FY2027 | "Phase 2/3 transition is expected in Q1 2027." exhibit |
| Q1 FY2027 | "Based on our current operating plan, we expect that our existing cash and cash equivalents and short-term investments, as of June 30, 2026, in addition to the $141.0 million of net proceeds from the issuance of our common stock in August 2026, will enable us to fund operations for greater than twelve months from the issuance of the condensed consolidated financial statements, which includes scale up for the commercialization of TUDRIQEV in advanced melanoma and for working capital and general corporate purposes." exhibit |
| Q4 FY2026 | "The FDA considers this a complete, class 1 response with a goal date of August 2, 2026, and has notified the company to expect an advisory committee meeting in late July." exhibit |
| Q4 FY2026 | "Phase 2/3 transition is expected in Q1 2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/REPL
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/REPL
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/REPL/"><img src="https://veritasdata.dev/embed/REPL.svg" alt="REPL earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/REPL/)
Script
<script async src="https://veritasdata.dev/embed/REPL.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/REPL"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.